Wall Street brokerages predict that Aptevo Therapeutics Inc (NASDAQ:APVO) will announce ($0.57) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Aptevo Therapeutics’ earnings. The highest EPS estimate is ($0.53) and the lowest is ($0.60). The firm is expected to announce its next quarterly earnings report on Tuesday, March 12th.

According to Zacks, analysts expect that Aptevo Therapeutics will report full year earnings of ($2.31) per share for the current financial year, with EPS estimates ranging from ($2.37) to ($2.27). For the next year, analysts anticipate that the firm will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.71) to ($1.71). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Aptevo Therapeutics.

Aptevo Therapeutics (NASDAQ:APVO) last posted its earnings results on Wednesday, November 14th. The biotechnology company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.01. The firm had revenue of $5.82 million during the quarter, compared to analysts’ expectations of $6.87 million. Aptevo Therapeutics had a negative net margin of 252.44% and a negative return on equity of 78.85%.

APVO has been the subject of a number of research reports. Zacks Investment Research raised shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a report on Tuesday, August 14th. ValuEngine upgraded shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, August 13th. Roth Capital set a $12.00 price objective on shares of Aptevo Therapeutics and gave the company a “buy” rating in a report on Thursday, November 15th. LADENBURG THALM/SH SH began coverage on shares of Aptevo Therapeutics in a report on Monday, November 5th. They issued a “buy” rating and a $14.00 price objective for the company. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $11.00 price objective on shares of Aptevo Therapeutics in a report on Friday, August 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Aptevo Therapeutics presently has an average rating of “Buy” and a consensus price target of $10.69.

Shares of APVO stock traded down $0.06 on Friday, reaching $2.20. The company had a trading volume of 41,500 shares, compared to its average volume of 142,096. The stock has a market capitalization of $54.68 million, a P/E ratio of -1.44 and a beta of 2.06. The company has a current ratio of 3.91, a quick ratio of 3.65 and a debt-to-equity ratio of 0.43. Aptevo Therapeutics has a one year low of $2.10 and a one year high of $6.35.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Northern Trust Corp raised its holdings in Aptevo Therapeutics by 21.2% in the 2nd quarter. Northern Trust Corp now owns 70,416 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 12,299 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Aptevo Therapeutics in the 2nd quarter valued at approximately $148,000. Dimensional Fund Advisors LP raised its holdings in Aptevo Therapeutics by 5.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,425,567 shares of the biotechnology company’s stock valued at $7,242,000 after buying an additional 73,911 shares during the last quarter. Acadian Asset Management LLC raised its holdings in Aptevo Therapeutics by 20.2% in the 3rd quarter. Acadian Asset Management LLC now owns 441,765 shares of the biotechnology company’s stock valued at $2,244,000 after buying an additional 74,256 shares during the last quarter. Finally, EAM Investors LLC bought a new position in Aptevo Therapeutics in the 2nd quarter valued at approximately $552,000. Institutional investors and hedge funds own 32.77% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

Read More: Dividend Stocks – Are They Right For You?

Get a free copy of the Zacks research report on Aptevo Therapeutics (APVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.